Search research articles
Contact Us
Filters
Showing results (61-70 of 250) with videos related to
Page
of 25
Sort By:
Annals of Hematology
|
October 15, 2016
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials
Maria-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 24, 2021
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma
Yael C Cohen, Albert Oriol, Ka Lung Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial
Judith Trotman, Christian Buske, Alessandra Tedeschi, et al.
Hematological Oncology
|
June 2, 2022
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
Thierry Facon, Philippe Moreau, Thomas G Martin, et al.
Future Oncology (London, England)
|
July 26, 2023
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
Ajai Chari, Elham Askari, Jo Caers, et al.
Clinical Transplantation
|
December 14, 2011
Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study
Manuela Aguilar-Guisado, Margarita Jiménez-Jambrina, Ildefonso Espigado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2008
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96
Josep-María Ribera, Albert Oriol, Miguel-Angel Sanz, et al.
Frontiers in Immunology
|
May 1, 2023
Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma
Yolanda Gonzalez-Montes, Rocío Rodriguez-Romanos, Alicia Villavicencio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2007
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics
Laura Rosiñol, Albert Oriol, Maria Victoria Mateos, et al.
Advances in Therapy
|
February 21, 2020
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses
Xu Steven Xu, Philippe Moreau, Saad Z Usmani, et al.
Page
of 25
Search research articles
Search
Showing results (61-70 of 250) with videos related to
Sort By:
Page
of 25
Annals of Hematology
|
October 15, 2016
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials
Maria-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 24, 2021
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma
Yael C Cohen, Albert Oriol, Ka Lung Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial
Judith Trotman, Christian Buske, Alessandra Tedeschi, et al.
Hematological Oncology
|
June 2, 2022
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
Thierry Facon, Philippe Moreau, Thomas G Martin, et al.
Future Oncology (London, England)
|
July 26, 2023
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
Ajai Chari, Elham Askari, Jo Caers, et al.
Clinical Transplantation
|
December 14, 2011
Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study
Manuela Aguilar-Guisado, Margarita Jiménez-Jambrina, Ildefonso Espigado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2008
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96
Josep-María Ribera, Albert Oriol, Miguel-Angel Sanz, et al.
Frontiers in Immunology
|
May 1, 2023
Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma
Yolanda Gonzalez-Montes, Rocío Rodriguez-Romanos, Alicia Villavicencio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2007
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics
Laura Rosiñol, Albert Oriol, Maria Victoria Mateos, et al.
Advances in Therapy
|
February 21, 2020
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses
Xu Steven Xu, Philippe Moreau, Saad Z Usmani, et al.
Page
of 25